Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VIRxSYS and the National Heart, Lung, and Blood Institute, a branch of the National Institute of Health, have signed a co-operative research and development agreement on atherosclerosis.
Subscribe to our email newsletter
One of the major aims of the research is to create ways of increasing the level of HDL cholesterol in the bloodstream using VIRxSYS’s patented spliceosome-mediated RNA trans-splicing (SMaRT) technology. SMaRT RNA therapy uses gene therapy vectors to deliver proprietary RNA molecules, known as ‘pre-trans-splicing molecules’ (PTMs), which can either correct defective gene sequences or provide a new function to a gene.
Riku Rautsola, president and CEO of VIRxSYS, said: “By combining VIRxSYS’s technology with the NHLBI’s know-how and experience, we will be able to develop new products with important benefits for the public.”